Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
The objective of this review was to merge current treatment guidelines and best practice recommendations for management of neuropathic pain into a comprehensive algorithm for primary physicians. The algorithm covers assessment, multidisciplinary Practice Guideline: Treatment of Restless Legs Syndrome in Adults This is a summary of the American Academy of Neurology (AAN) guideline, “Treatment of restless legs syndrome in adults,” which was published in Neurology® online on November 16, 2016, and appears in the December 13, 2016, print issue. Graded treatment recommendations can be found in treatment topics for specific chronic pain conditions (eg, chronic back pain, postherpetic neuralgia, fibromyalgia). The general approach to the management of chronic non-cancer pain and nonpharmacologic therapies for chronic pain are discussed separately. Treatment should commence at 300 mg of gabapentin (100 mg in patients older than 65 years) or 75 mg of pregabalin daily (50 mg in patients older than 65 years) and be increased every few days as needed. Most RLS patients require 1200 to 1800 mg of gabapentin daily, but doses up to 3600 mg daily can be used. Gabapentin was first approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures in 1993 and was subsequently approved for one pain indication, postherpetic neuralgia. Guidelines for the diagnosis and treatment of patients with trigeminal neuralgia (TN) advocate for a multidisciplinary team approach to improve the care of patients with acute and chronic TN. Evidence-based discussions and decisions are encouraged to establish care pathways for prompt diagnosis and treatment, and long-term outcomes data collection to improve care. The guidelines include Chronic Non Malignant Pain Neuropathic Pain Guidelines, GGC A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments. The MHRA and manufacturers advise that when prescribing gabapentin in patients who require concomitant treatment with opioid medicines, patients should be carefully observed for signs of CNS depression, such as somnolence, sedation, and respiratory depression, and the dose of either gabapentin or the opioid should be reduced appropriately.6,7 Treatment is focused on symptom control and includes topical lidocaine or capsaicin and oral gabapentin, pregabalin, or tricyclic antidepressants. Gabapentin is licensed for the treatment of peripheral neuropathic pain such as painful diabetic neuropathy and postherpetic neuralgia in adults [ABPI, 2020a]. However, the National Institute for Health and Care Excellence (NICE) recommends gabapentin as a first-line treatment option for adults with all neuropathic pain (except trigeminal neuralgia) [NICE, 2019a]. The guideline is based on a systematic review of the current scientific literature regarding antiepileptic drugs in the treatment of chronic pain (neuropathic and somatic, musculoskeletal pain) and is limited to the following newer AEDs: gabapentin, lamotrigine (Lamictal), levetiracetam (Keppra), oxcarbazepine (Trileptal), tiagabine (Gabitril), topiramine (Topamax), and zonisamide (Zonegran). (1) Gabapentin for the treatment of nerve pain Patient Information Leaflet If you have any questions about your medication please ask your doctor, nurse, or pharmacist. The U.S. Department of Veterans Affairs and U.S. Department of Defense (VA/DoD) published updated guidelines for the treatment of headache disorders based on a systematic review. Introduction:This guideline establishes clinical practice recommendations for treatment of restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) in adults and pediatric patients.M A new clinical practice guideline developed by the AASM provides updated recommendations for the treatment of restless legs syndrome. These guidelines represent a decision guide based on scientific evidence that is intended to aid physicians in the choice of an appropriate treatment regimen and to facilitate optimal use of the chosen treatment option. 3.1 Development of recommendations: strength of recommendations, wording, and symbols Overview of pharmacologic management of chronic pain in adults, including medication options and treatment strategies. Gabapentin in alcohol withdrawal: For the first time, the DSM-V includes the diagnostic guidelines for alcohol dependency. A variety of severe conditions result from or are influenced by alcohol dependence, including stomach ulcers, liver disorders, increased risk of heart disease, and neuropathy. The Neuropathic Pain Special Interest Group of the International Association for the Study of Pain recently sponsored the development of evidence-based guidelines for the pharmacological treatment of neuropathic pain. Tricyclic antidepressants, dual reuptake inhibitors of serotonin and norepinephrine, calcium channel α2-δ ligands (ie, gabapentin and pregabalin), and topical lidocaine were NICE Clinical guideline 173 states “Offer a choice of amitriptyline, duloxetine, gabapentin or pregabalin as initial treatment for neuropathic pain (except trigeminal neuralgia)”. Pregabalin and duloxetine are recommended as initial treatment options due to their wider licences, however the full guideline for CG173 acknowledges that both these treatments represent poor value for money and
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |